Israeli Jews

Mattel Names Jonathan Anschell Executive Vice President, Chief Legal Officer, and Secretary

Retrieved on: 
Tuesday, December 8, 2020

Mattel, Inc. (NASDAQ: MAT) today announced the appointment of Jonathan Anschell as Executive Vice President, Chief Legal Officer, and Secretary, effective Jan. 1, 2021.

Key Points: 
  • Mattel, Inc. (NASDAQ: MAT) today announced the appointment of Jonathan Anschell as Executive Vice President, Chief Legal Officer, and Secretary, effective Jan. 1, 2021.
  • Anschell will report to Ynon Kreiz, Mattels Chairman and Chief Executive Officer.
  • I look forward to Jonathan joining the executive leadership team as we build on the momentum already well underway at Mattel and create value for our shareholders.
  • Anschell brings extensive legal, corporate governance and media and entertainment industry expertise to Mattel.

Mattel Chairman and CEO Ynon Kreiz to Participate in Virtual Barclays Eat, Sleep, Play Conference

Retrieved on: 
Monday, November 30, 2020

Mattel, Inc. (NASDAQ: MAT) today announced that Chairman and Chief Executive Officer Ynon Kreiz will participate in a fireside chat at the virtual Barclays Eat, Sleep, Play Conference on Tuesday, December 1, 2020 at 10:30 a.m. Eastern time.

Key Points: 
  • Mattel, Inc. (NASDAQ: MAT) today announced that Chairman and Chief Executive Officer Ynon Kreiz will participate in a fireside chat at the virtual Barclays Eat, Sleep, Play Conference on Tuesday, December 1, 2020 at 10:30 a.m. Eastern time.
  • The webcast will be available on Mattels Investor Relations website, https://mattel.gcs-web.com/ .
  • An archive of the webcast will be available on the Companys website shortly after the completion of the live webcast.
  • Mattel is a leading global toy company and owner of one of the strongest catalogs of childrens and family entertainment franchises in the world.

Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference

Retrieved on: 
Thursday, November 19, 2020

BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

Key Points: 
  • BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
  • Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need.
  • Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

ControlUp announces $27M Funding, Led by JVP and K1, After a Breakthrough 2020

Retrieved on: 
Wednesday, November 18, 2020

"As we look across the business sector over the last year, it is clear that every industry has been impacted.

Key Points: 
  • "As we look across the business sector over the last year, it is clear that every industry has been impacted.
  • "ControlUp leads the next generation of performance automation of information systems, distributed among offices and endpoints, in any organization, anytime, anywhere, in a virtual or physical environment.
  • It gives the organization a complete picture of its network performance," says Erel Margalit, founder and chairman of JVP.
  • Jerusalem Venture Partners (JVP) , founded and led by Dr. Erel Margalit, is an internationally renowned venture capital fund.

ControlUp announces $27M Funding, Led by JVP and K1, After a Breakthrough 2020

Retrieved on: 
Wednesday, November 18, 2020

"As we look across the business sector over the last year, it is clear that every industry has been impacted.

Key Points: 
  • "As we look across the business sector over the last year, it is clear that every industry has been impacted.
  • "ControlUp leads the next generation of performance automation of information systems, distributed among offices and endpoints, in any organization, anytime, anywhere, in a virtual or physical environment.
  • It gives the organization a complete picture of its network performance," says Erel Margalit, founder and chairman of JVP.
  • Jerusalem Venture Partners (JVP) , founded and led by Dr. Erel Margalit, is an internationally renowned venture capital fund.

Exclusive from Long Island University - Former Israeli Prime Minister Ehud Olmert Hopes Biden Has the "Courage" to Return to the 2015 Iran Nuclear Deal and Renegotiate "an Even Better Agreement." Says Trump and Netanyahu Both Failed as Leaders in Handling

Retrieved on: 
Saturday, November 14, 2020

The former prime minister says of Biden's approach to the Israeli-Palestinian conflict, "Joe Biden's attitude is the right attitude.

Key Points: 
  • The former prime minister says of Biden's approach to the Israeli-Palestinian conflict, "Joe Biden's attitude is the right attitude.
  • During the webinar, Olmert acknowledged "Donald Trump was a friendly president to the State of Israel, there is no question about it.
  • During the wide-ranging webinar, Olmert was very critical of Netanyahu and hopes his days in office may soon come to an end.
  • There are many ways, effective ways, to deal with the impact of COVID-19 to reduce the damages that it causes.

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020

Retrieved on: 
Thursday, November 12, 2020

Prof. Hershko is a member of the Oramed Scientific Advisory Board.

Key Points: 
  • Prof. Hershko is a member of the Oramed Scientific Advisory Board.
  • ET, in the conclusion of a two-part webinar series, the session will focus on the "Oral Delivery of Therapeutic Proteins - Oramed Story".
  • Oramed Pharmaceuticalsis a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices inNew YorkandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology.

Long Island University's Global Service Institute Chair, Famed Broadcaster Rita Cosby to Host Former Israeli Prime Minister Ehud Olmert on Nov. 12

Retrieved on: 
Wednesday, November 11, 2020

BROOKVILLE, N.Y., Nov. 11, 2020 /PRNewswire/ --The Headliners of Service virtual speaker series at Long Island University's Global Service Institute will continue on Thursday, Nov. 12 at NoonEST, with a live conversation with former Israeli Prime Minister Ehud Olmert.

Key Points: 
  • BROOKVILLE, N.Y., Nov. 11, 2020 /PRNewswire/ --The Headliners of Service virtual speaker series at Long Island University's Global Service Institute will continue on Thursday, Nov. 12 at NoonEST, with a live conversation with former Israeli Prime Minister Ehud Olmert.
  • Moderated by Global Service Institute Chair and acclaimed journalist Rita Cosby, the complimentary virtual lecture will be held through Zoom, open to the public, and will follow with a live Q&A period for viewers.
  • The Global Service Institute's mission is to become the preeminent service initiative in education.
  • Long Island University, founded in 1926, continues to redefine higher education, providing high quality academic instruction by world-class faculty.

Mattel Chairman and CEO Ynon Kreiz to Participate in Virtual Berenberg US CEO Conference

Retrieved on: 
Wednesday, November 11, 2020

Mattel, Inc. (NASDAQ: MAT) today announced that Chairman and Chief Executive Officer Ynon Kreiz will participate in a fireside chat at the virtual Berenberg US CEO Conference on Thursday November 12, 2020 at 12:00 p.m. Eastern time.

Key Points: 
  • Mattel, Inc. (NASDAQ: MAT) today announced that Chairman and Chief Executive Officer Ynon Kreiz will participate in a fireside chat at the virtual Berenberg US CEO Conference on Thursday November 12, 2020 at 12:00 p.m. Eastern time.
  • The webcast will be available on Mattels Investor Relations website, https://mattel.gcs-web.com/ .
  • An archive of the webcast will be available on the Companys website shortly after the completion of the live webcast.
  • Mattel is a leading global toy company and owner of one of the strongest catalogs of childrens and family entertainment franchises in the world.

Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Tuesday, November 10, 2020

LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time.
  • A live audio webcast of the presentation can be accessed through the Investors section of the companys website at mereobiopharma.com/investors/results-reports-and-presentations .
  • An archived replay of the webcast will be available on the companys website for two weeks following the live presentation.
  • Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases.